ADiTx Therapeutics Inc. (ADTX): Price and Financial Metrics

ADiTx Therapeutics Inc. (ADTX): $0.85

-0.03 (-3.73%)

POWR Rating

Component Grades













Add ADTX to Watchlist
Sign Up

Industry: Biotech



in industry


  • ADTX scores best on the Growth dimension, with a Growth rank ahead of 90.5% of US stocks.
  • ADTX's strongest trending metric is Momentum; it's been moving down over the last 165 days.
  • ADTX ranks lowest in Momentum; there it ranks in the 1st percentile.

ADTX Stock Summary

  • With a market capitalization of $3,786,627, ADITXT INC has a greater market value than just 0.99% of US stocks.
  • Revenue growth over the past 12 months for ADITXT INC comes in at 712.26%, a number that bests 98.74% of the US stocks we're tracking.
  • ADITXT INC's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -977.73%, greater than the shareholder yield of just 0.75% of stocks in our set.
  • If you're looking for stocks that are quantitatively similar to ADITXT INC, a group of peers worth examining would be NVVE, VBIV, MMAT, WEAV, and LMND.
  • To check out ADITXT INC's SEC filings, go to the company's page on browse-edgar?action=getcompany&CIK=0001726711.

ADTX Valuation Summary

  • ADTX's price/earnings ratio is -0.1; this is 100.44% lower than that of the median Healthcare stock.
  • Over the past 33 months, ADTX's EV/EBIT ratio has gone up 4.8.

Below are key valuation metrics over time for ADTX.

Stock Date P/S P/B P/E EV/EBIT
ADTX 2023-03-17 4.3 0.3 -0.1 0.1
ADTX 2023-03-16 4.8 0.3 -0.1 0.0
ADTX 2023-03-15 4.9 0.3 -0.1 0.0
ADTX 2023-03-14 5.0 0.3 -0.1 0.0
ADTX 2023-03-13 5.2 0.3 -0.1 0.0
ADTX 2023-03-10 5.2 0.3 -0.1 0.0

ADTX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • ADTX has a Quality Grade of D, ranking ahead of 6.37% of graded US stocks.
  • ADTX's asset turnover comes in at 0 -- ranking 440th of 682 Pharmaceutical Products stocks.
  • 500 - Internal server error

The table below shows ADTX's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0 NA -3.828
2021-03-31 0 NA -7.358
2020-12-31 0 NA 37.006

ADTX Price Target

For more insight on analysts targets of ADTX, see our ADTX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $14.00 Average Broker Recommendation 1.5 (Moderate Buy)

ADTX Stock Price Chart Interactive Chart >

Price chart for ADTX

ADTX Price/Volume Stats

Current price $0.85 52-week high $28.49
Prev. close $0.89 52-week low $0.83
Day low $0.83 Volume 19,300
Day high $0.89 Avg. volume 167,088
50-day MA $1.23 Dividend yield N/A
200-day MA $4.24 Market Cap 3.55M

ADiTx Therapeutics Inc. (ADTX) Company Bio

ADiTx Therapeutics, Inc. is a preclinical stage, life sciences company which engages in the development of nucleic acid (DNA)-based technologies to minimize rejection of transplanted organs by human recipients as well as address autoimmune diseases and allergies. The firm have worldwide license for commercializing a nucleic acid-based technology, named Apoptotic DNA Immunotherapy (ADi), which utilizes a novel approach that mimics the way the body naturally induces tolerance to its own tissue. The company was founded by Leonard L. Bailey, Shahrokh Shabahang, and Amro Albanna on September 28, 2017 and is headquartered in Loma Linda, CA.

ADTX Latest News Stream

Event/Time News Detail
Loading, please wait...

ADTX Latest Social Stream

Loading social stream, please wait...

View Full ADTX Social Stream

Latest ADTX News From Around the Web

Below are the latest news stories about ADITXT INC that investors may wish to consider to help them evaluate ADTX as an investment opportunity.

Aditxt Names Media Industry Veteran Maureen Connolly as Chief Content and Engagement Officer

RICHMOND, Va., March 08, 2023--Aditxt, Inc., (NASDAQ: ADTX) ("Aditxt" or the "Company"), an innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, is pleased to announce Maureen Connolly has joined Aditxt as Chief Content and Engagement Officer. Connolly is an award-winning content strategist and audience builder with 25+ years of experience in the health, science, wellness, technology, and chronic conditions space. She works w

Yahoo | March 8, 2023

Aditxt Retains Riverside Management Group as Advisor to Support Strategic M&A Driven Acquisitions by Subsidiary Pearsanta, Inc.

RICHMOND, Va., March 03, 2023--Aditxt, Inc., (NASDAQ: ADTX) ("Aditxt" or the "Company"), an innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, today announces it has retained Riverside Management Group, LLC ("Riverside Management Group" or "RMG"), a merchant banking firm providing investment banking advisory services, to support the Company’s ongoing growth and revenue generating plans for its subsidiary Pearsanta, Inc. ("P

Yahoo | March 3, 2023

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

It's time to start off trading on Friday with a breakdown of the biggest pre-market stock movers worth keeping an eye on!

William White on InvestorPlace | February 24, 2023

Aditxt Forms its Second Subsidiary, Pearsanta, Inc., to Accelerate the Growth of its AditxtScore™ Program and Appoints Healthcare Executive and Current Head of AditxtScore™ Anthony Voorhies to Serve as its President

RICHMOND, Va., February 14, 2023--Aditxt, Inc., (NASDAQ: ADTX) ("Aditxt" or the "Company"), an innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, today announces the formation of a U.S.-based wholly- owned subsidiary, Pearsanta, Inc. ("Pearsanta"), to accelerate the growth of Aditxt’s second program, AditxtScore™, through future strategic revenue and growth-oriented transactions.

Yahoo | February 14, 2023

Is the Options Market Predicting a Spike in Aditx (ADTX) Stock?

Investors need to pay close attention to Aditx (ADTX) stock based on the movements in the options market lately.

Yahoo | January 12, 2023

Read More 'ADTX' Stories Here

ADTX Price Returns

1-mo -27.97%
3-mo -24.78%
6-mo -72.13%
1-year -96.28%
3-year N/A
5-year N/A
YTD -26.38%
2022 -95.69%
2021 -74.23%
2020 N/A
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7861 seconds.